Annals of Hepato-Biliary-Pancreatic Surgery

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2508-5859   pISSN 2508-5778

Table. 2.

Table. 2.

Patient characteristics and treatment details

Study Number of patients Age (years) Gender (% male) Indication Number of cycles Dialysate 90-day mortality
MARS
Chiu et al. (2006)18 4 64.0 4 (100%) HCC–3 (75%)CC–1 (25%) 2.5±0.5 600 ml of 20% human albumin 4 (100%)
Gilg et al. (2018)19 10 69.5 6 (60%) HCC–1 (10%)LM–5 (50%)CC–4 (40%) 5.8±1.0 Renal dialysis dose of 35 ml/kg/hour 1 (10%)
Rusu et al. (2009)20 2 54.0 1 (50%) HCC–1 (50%)LM–1 (50%) Mean=1.0 Dialysate with a bicarbonate-based buffer system 0 (0%)
Saliba et al. (2013)21 13 NR NR NR 3.5±1.9 NR 92%*
van de Kerkhove et al. (2003)22 5 60.0 4 (80%) HCC–1 (20%)LM–3 (60%)CC–1 (20%) 5.2±2.5 NR 4 (80%)
PE
Asanuma et al. (2003)23 2 65.0 2 (100%) HCC–1 (50%)LM–1 (50%) Mean=9.0 5% albumin solution plus FFP or FFP alone 0 (0%)
Lee et al. (2017)24 3 67.0 2 (67%) HCC–1 (33%)CC–2 (67%) 5.3±2.5 FFP alone 0 (0%)
Usami et al. (1989)25 8 56.5 NR HCC–8 (100%) 28.5±38.6 NR 5 (63%)
Yonekawa et al. (2005)26 7 63.0 6 (86%) HCC–4 (57%)LM–1 (14%)PHCC–2 (29%) 5.0±4.0 5% albumin solution plus FFP or FFP alone 3 (43%)

Ages reported as medians, Numbers of cycles reported as mean±SD, unless stated otherwise. Percentages are calculated manually, based on the numbers reported in the studies

*Six month mortality rate

FFP, fresh frozen plasma; HCC, hepatocellular carcinoma; LM, liver metastases; PHCC, perihilar cholangiocarcinoma; NR, not reported

Ann Hepatobiliary Pancreat Surg 2021;25:171-8 https://doi.org/10.14701/ahbps.2021.25.2.171
© 2021 Ann Hepatobiliary Pancreat Surg